Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05203965 · ClinicalTrials.gov registry record · Early Phase 1
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant
A Early Phase 1 study of Familial Alcoholism Vulnerability, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05203965 is a Early Phase 1 study of Familial Alcoholism Vulnerability that is actively recruiting participants, run by Yale University. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05203965, a Early Phase 1 study of Familial Alcoholism Vulnerability, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mavoglurant (AFQ056)
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-05-17 |
| Est. Completion | 2026-07-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05203965
The ClinicalTrials.gov registry entry for NCT05203965 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Familial Alcoholism Vulnerability appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05203965 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05203965 about?
NCT05203965 is a clinical study titled "Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant". The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.
What is the current status of trial NCT05203965?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2022-05-17. Estimated completion is 2026-07-31.
What conditions does trial NCT05203965 study?
This clinical trial studies the following conditions: Familial Alcoholism Vulnerability.
What interventions are being tested in trial NCT05203965?
The interventions under investigation include: Placebo (DRUG), Mavoglurant (AFQ056) (DRUG).
Who is sponsoring clinical trial NCT05203965?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05203965 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.